Douglas A. Levine, M.D.
Director, Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center
Head, Gynecology Research Laboratory
Professor, Divison of Gynecologic Oncology, Department of OB/GYN
NYU Langone Medical Center
I am a gynecologic oncologist who specializes in the surgical treatment of women with known or suspected ovarian or uterine cancers.
In addition to caring for patients, I head the Gynecology Research Laboratory, where my efforts focus on the genomics of ovarian and endometrial cancers. Specifically, I am trying to identify clinically relevant genomic predictors of outcome for women with ovarian or endometrial cancer. A major portion of my research also focuses on studying molecular profiles of women who are treated with novel targeted anticancer drugs. Our goal is to determine which patients are most likely to respond to a given therapy so that we can direct the best treatments toward the most appropriate patients. I use whole-genome microarray techniques and other methods to molecularly characterize ovarian and uterine cancers from patients treated at Memorial Sloan Kettering and on national cooperative group clinical trials. My research is supported by funding from the National Cancer Institute, the Department of Defense, Stand Up To Cancer, the Ovarian Cancer Research Fund, the Gynecologic Cancer Foundation, and the Entertainment Industry Foundation.
I also have an active interest in medical education and innovative technology. I have authored or co-authored more than 85 peer-reviewed research papers, review articles, and book chapters. I am also the founding editor of Atlas of Procedures in Gynecologic Oncology — the only full-color photographic surgical atlas in the field — which is now in its second edition. I serve on the editorial boards of Gynecologic Oncology and Ovarian Cancer and am co-chair of both the Ovarian and Endometrial Cancer Working Groups of The Cancer Genome Atlas.
My goals are to provide the highest quality comprehensive care to women with gynecologic cancers and improve patient outcomes through research and education.
For most women with these cancers, surgery is an important part of the initial treatment and increases the possibility of a cure. Many studies have shown that women with gynecologic cancers have better outcomes when their primary surgery is performed by a gynecologic oncologist. In addition to my expertise in the surgical management of gynecologic cancers, I also have special training in minimally invasive surgery (laparoscopy) and preventive surgery for appropriately selected patients. Intraperitoneal chemotherapy has been proven to be a superior method of treatment for advanced ovarian cancer, and I fully incorporate this into the treatment of appropriate patients. I also perform single-incision laparoscopic surgery (SILS) in appropriate cases, which reduces the number of surgical incisions or scars from four down to only one.
Follow Dr. Levine on Twitter @levinemd.